不同药物吸入治疗对新生儿肺炎的疗效评价

目的探讨沐舒坦和糜蛋白酶不同雾化方式治疗新生儿肺炎的临床疗效及安全性。方法将我院2011年7月至2013年8月明确诊断的78例新生儿肺炎患儿按照随机数字表法随机分为治疗组和对照组，每组39例。两组患儿在综合治疗基础上，对照组应用糜蛋白酶雾化，治疗组予沐舒坦压缩雾化，观察两组治疗疗效。结果与治疗后24、48、72h比较，治疗组患儿PaO2较对照组明显上升，PaCO2较对照组明显下降，氧合指数较对照组升高明显改善，差异均有统计学意义（P〈0．01）。治疗组在症状缓解、体征消失时间和住院天数较对照组缩短，与对照组比较差异有统计学意义（P〈0．01）；治疗组中显效25例，有效9例，无效5例，有效率为87．2％。对照组中显效14例，有效6例，无效19例，有效率为51．3％，两组间差异有统计学意义（P〈0．01）。两组在治疗过程中均未发现相关的药物不良反应。结论雾化吸入治疗新生儿肺炎沐舒坦疗效优于糜蛋白酶，缩短疗程，值得推广应用。

Evaluation of the treatment effect of inhalation of different drug on neonatal pneumonia

Objective To investigate the clinical efficacy and its security on different kinds of atom- ization with mucosolvan and chymotrypsin in treating neonatal pneumonia. Methods Seventy-eight neonates who were diagnosed as neonatal pneumonia were divided into treatment group （ n = 39 ） and control group （n = 39） by random number table method from Jul 2011 to Aug 2013 in our hospital. The control group was treated with chymotrypsin atomization, and the treatment group was treated with compression atomizing to inhale mucosolvan. The treatment effects of two groups were compared. Results Compared with the control group after treatment for 24 b,48 h,72 h, the treatment group had more significant increasing in PaO2, more decreasing in PaCO2 and more significant improvement in oxygenation index. There were statistical significances between the two groups（ P 〈 0. 01 ）. The treatment group spent shorter time in remission of symptoms, disappear of signs and hospital stay than that of the control group（ P 〈 0. 05 ）. In the treatment group ,25 cases were markedly improved,9 cases were effective,5 cases were invalid. The effective rate was 87.2%. In the control group, 14 cases were markedly effective,6 cases were effective, 19 cases were invalid. The effective rate was 51.3%. The effective rate was significant difference between the two groups （ P 〈 0. 01 ）. The adverse drug reactions were not found in the process of treatment for two groups. Conclusion Mucosolvan atomizing inhalation has a better treatment effect than chymotrypsin. It can shorten the course of treatment, and is worth promoting the application.